DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer

Category VRDN

Viridian Therapeutics Inc

3 Biotech Stocks Facing Near-Term FDA Catalysts: MannKind ($MNKD), Viridian Therapeutics ($VRDN) and Vera Therapeutics ($VERA)

Biotech

Biotech does not need to be vague to be speculative. The best watchlist stories usually sit in the middle: visible enough to be researched, near enough to matter, but still uncertain enough to create price discovery. MannKind ($MNKD), Viridian Therapeutics ($VRDN) and Vera Therapeutics ($VERA) fit that profile heading into late May, June and July 2026.

Viridian Therapeutics ( $VRDN ): why the stock crashed on “positive” REVEAL-1 data

Viridian’s REVEAL-1 press release was positive in the narrow, technical sense that matters most for binary biotech trading: the phase 3 trial hit its primary endpoint. Elegrobart, the company’s subcutaneous IGF-1R antibody for active thyroid eye disease, delivered a 54% proptosis responder rate in the every-four-week arm and 63% in the every-eight-week arm, versus 18% on placebo. The Q4W arm also showed strong diplopia data, including 51% complete resolution versus 16% on placebo. That is not failure language. That is a live asset with real activity. And yet the stock was hit as if something had gone badly wrong.

VRDN Viridian Therapeutics Inc

Viridian Therapeutics (VRDN) has started 2026 by reaffirming its "transformational" year narrative in the January 6 PR, which serves as a comprehensive roadmap update without any timeline shifts or negative surprises. This builds directly on the December 22, 2025 BLA acceptance for veligrotug (VRDN-001) in TED with Priority Review and PDUFA target of June 30, 2026 (as detailed in the previous report).

VRDN Viridian Therapeutics Inc

Viridian Therapeutics is trying to become the second major commercial player in thyroid eye disease after Amgen’s Tepezza, with a TED franchise built around veligrotug (IV) and VRDN-003 (subcutaneous), plus an FcRn platform (VRDN-006/008) that targets broader autoimmune indications.

$VRDN

Grafico trading Forex con analisi di volatilità e trend di mercato, piattaforma Merlintrader Trading Pub.

Grafico è interessante, bel canale rialzista. Incamminata verso i suoi catalyst; non male se si riesce a prendere alla base del canale. Ha pochi volumi giornalieri il chè non mi piace tanto. Cmq interessante. Viridian Therapeutics (VRDN) — Merlintrader Report…